RxDoctor Payments Data

Stephen Treadwell, DO

Family Medicine · Healdton, OKNPI 1447299920

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 74 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$340
  • Johnson & Johnson$207
  • Lilly USA, LLC$142
  • Takeda Pharmaceuticals U.S.A., Inc.$74
  • Bayer$74
  • Pfizer$68
  • plus $281 from 10 others

What the payments were for

  • Food & beverage$1,17699%
  • Education$101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,186 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$169,018
Medicare patients
188
Services billed
3,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide206$277,026
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$64,541
JardianceEmpagliflozin52$57,302
EliquisApixaban75$42,771
VraylarCariprazine Hcl38$36,438
Tresiba Flextouch U-200Insulin Degludec41$32,083
LinzessLinaclotide27$22,146
TrintellixVortioxetine Hydrobromide20$13,957
KerendiaFinerenone24$11,480
Celecoxib172$10,566
RexultiBrexpiprazole14$9,618
MyrbetriqMirabegron16$6,846
Dexlansoprazole DrDexlansoprazole27$6,573
Breo ElliptaFluticasone/Vilanterol16$6,149
EntrestoSacubitril/Valsartan14$5,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$340$277,026206 claims
Boehringer IngelheimJardiance$31$57,30252 claims
PfizerEliquis, Levoxyl$68$46,364180 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$74$13,95720 claims
BayerKerendia$74$11,48024 claims
NovartisEntresto$60$5,85614 claims
MerckJanuvia$13$3,47812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Healdton

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →